To Analyze the Clinical Efficacy of Cisplatin Combined with Pemetrexed in the Treatment of Advanced Non-squamous Non-small Cell Lung Can-cer
Objective To evaluate the efficacy of combination therapy of cisplatin and pemetrexed in patients with ad-vanced non-squamous non-small cell lung cancer.Methods Sixty patients with advanced non-squamous non-small cell lung cancer admitted to the Oncology Department of Qianxi People's Hospital from January 2022 to December 2023 were non-randomly selected as the study subjects,and divided into two groups according to different treatment methods,with 30 patients in each group,respectively receiving pemetrexed monotherapy(pemetrexed group)and pemetrexed plus cisplatin combined therapy(combined cisplatin group).Compared the treatment effect between the two groups,Serum tumor markers[neuronspecific enolase(NSE),cytoplasmic keratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)],And the quality of life score and the occurrence of adverse reac-tions.Results The total effective rate of the combined cisplatin group was 66.67%(20/30)higher than 26.67%(8/30)of pemetrexed group,and the difference was statistically significant(χ2=10.111,P<0.05).After 1 cycle of chemo-therapy,the serum levels of NSE,Cyfra21-1 and CEA in 2 groups were lower than before chemotherapy,and the com-bined cisplatin group was lower than pemetrexed group,the difference were statistically significant(all P<0.05).After chemotherapy combined with cisplatin group was better than pemetrexed group,the differences were statistically sig-nificant(all P<0.05).The incidence of adverse reactions in combination with cisplatin group was lower than that in pemetrexed group,and the difference was statistically significant(P<0.05).Conclusion For advanced non-squamous non-small cell lung cancer,the combination of cisplatin and pemetrexed can effectively improve the treatment re-sponse rate,reduce the level of serum tumor markers,maintain the quality of life of patients,and show a good safety.
万方数据
维普
